Breaking News

A controlled study of adalimumab with or without calcipotriol/betamethasone ointment in moderate-severe psoriasis

A controlled study of adalimumab with or without calcipotriol/betamethasone ointment in moderate-severe psoriasis

 
 

A 16-week, pan European, multicenter, randomized, double-blind, vehicle-controlled study evaluated the efficacy and safety of adalimumab with or without calcipotriol/betamethasone (C/B) ointment in 730 patients with moderate-severe psoriasis. They had all been suboptimally treated previously with more than two systemic treatments. All patients received adalimumab (80 mg/week at week 0 then 40 mg/week on weeks 1-15) either with (n = 366) or without (n = 364) topical C/B. The C/B or vehicle was applied once daily for 4 weeks and as necessary thereafter. The primary endpoint was a 75% or greater reduction in the Psoriasis Area and Severity Index (PASI) from baseline to week 16. At week 16, there was no ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list